Filing Flows › Harvard Apparatus Regenerative Technology (HRGN) › Recalls, complaints & regulation

Harvard Apparatus Regenerative Technology (HRGN): clinical trials

Harvard Apparatus Regenerative Technology (HRGN) beyond its filings: 1 active clinical trial.

Harvard Apparatus Regenerative Technology's latest quarter

Harvard Apparatus Regenerative Technology, Q2 2026: revenue $414K (+31% year over year), operating margin -408.7%, net loss $1.7M, operating cash flow −$569K. The chart follows the revenue to costs, profit and cash.

Questions

How many clinical trials does Harvard Apparatus Regenerative Technology have?

1 active study on ClinicalTrials.gov, 0 in phase 3.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.